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Pulmonary alveolarmicrolithiasis (PAM) is a rare autosomal recessive disorder characterized by the
deposition of calcium phosphate microliths throughout the lungs. Currently the mutation of
SLC34A2 genewas considered responsible for PAM. Herewe reported the studies onmutation anal-
ysis of the SLC34A2 gene in three familialmembers and one unrelated subject of PAMbyDNAdirect
sequencing. Meanwhile, we also reviewed and analyzed the published studies of the SLC34A2 gene
mutation in PAM patients. The three familial patients were siblings of an inbred family whose
parents were cousins. All four patients presented recurrent cough and exertional dyspnea. Diag-
nosis of PAMwasmade according to the typical manifestation of radiology. One homozygousmuta-
tion of the SLC34A2 gene, c.910A > T (p.K304X) was identified. The review of the SLC34A2 gene
mutation showed multiple mutation symbols in PAM patients from China, Turkey, and Japan
respectively. The present study supports that the clinical features, pathological and radiological
characteristics of Chinese PAM patients are similar to those reported in other countries. Our inves-
tigation revealed that the c.910A > T mutation in the SCL34A2 gene was responsible for PAM
patients in China. The review of literatures suggests that exon7 and exon8 seemed liable to be
affected typical Mongoloid of PAM, and exon8 might be the screen target for Chinese patients.
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com (H. Wang).
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fields of chest CT scan.Pulmonary alveolar microlithiasis (PAM [MIM 265099]) is
a rare disease characterized by the deposition of calcium
phosphate microliths throughout the lungs. It was first
described by Puhr in 1933.1 Most patients are either
asymptomatic for several years or even decades, or only
complaining symptoms such as intermittent mild cough or
slowly progressive dyspnea. The onset age of this poten-
tially lethal disease varies from the neonatal period to 80
years.2 Following a chronic progressive course, PAM
generally results in a slow deterioration of lung function.3
A sandstorm-like chest roentgenogram is a typical diag-
nostic finding. A variety of environmental factors have
been suggested as the etiology, nevertheless, about one-
third of the reported cases are familial.4e6 The most
comprehensive report that described more than 500 cases
worldwide in 2004 revealed that the prevalence of PAM
was predominated in Europe (42.7%) and Asia (40.6%).4
And Japan, Turkey and India are the main source of PAM
cases in Asia.7 However, very limited data concerning to
Chinese PAM patients were reported.8e15 Recently, muta-
tion in the SLC34A2 gene, which encodes the sodium
dependent phosphate transporter, is considered to be
responsible for PAM.8,16e19 However, its mutation symbols
in different cases are not investigated yet for its limited
data. Here we described a novel mutation of the SLC34A2
gene in an inbred family and a sporadic one, and rean-
alyzed the existing data of different mutations previously
reported.
Materials and methods
Subjects and ethical considerations
A consanguineous family (see Fig. 1A) and one unrelated,
sporadic PAM patient (see Fig. 1B) were recruited for this
study. Patients were diagnosed based on characteristic
chest X-ray and computer tomography (CT) findings.
Written informed consent was obtained from either the
patient or from an authorized family member. The study
was approved by the Committee on Research with Human
Participants at Zhejiang University.
Patients from the consanguineous family
Family member Ⅱ:9, a non-smoking male worker, was
diagnosed of PAM at the age of 25 years in a routine
checkup.9 Eight years later, he gradually developed chronic
cough and exercise-induced dyspnea. Follow-up chest CT
scans revealed diffuse fine sand-like high density shadows
in bilaterally fields, especially concentrated in the mid-
lower zones. He was followed up once a year for more
than thirty years and showed stable status. His parents
were first cousins, the mother was healthy with normal
chest X-ray manifestations, and the father deceased on his
seventy year without case history. His two deceased sisters
(Ⅱ:3 and Ⅱ:11) were both patients of PAM, the younger one
(Ⅱ:11) was the proband. Both of them were diagnosed in
a high school regular checkup asymptomatically, developed
respiratory failure 30 years later and finally succumbed to
the disease five years ago. Ⅱ:1, the elder brother of Ⅱ:9,and Ⅲ:6, the son of Ⅱ:9, were unaffected with clear lung
The sporadic patient from a non-inbred family
This sporadic patient is a 42-year-old, non-smoking female,
without any relationship to the foresaid family according to
the detail survey of ancestry. She was also identified in
a regular checkup at the age of 20. She kept asymptomatic
until her 40s when she started experiencing exertional
dyspnea. Physical examination revealed normal breath
sound. Pulmonary function test demonstrated moderate
impairment of ventilation function. A thorough survey of
her family excluded the possibility of inbred marriage of
her parents who were healthy. The Chest X-rays of all the
family including her three brothers and a 20-year-old
daughter were normal.
Genetic analysis
Genomic DNA was isolated from peripheral blood samples of
the three men in the family (individuals Ⅱ:1, Ⅱ:9, Ⅲ:6 in the
pedigree shown in Fig. 1A), the sporadic PAM patient
(individual Ⅱ:7 in the pedigree shown in Fig. 1B) and 100
healthy volunteers using standard protocols. Applying
online software of Primer3, 13 pairs of primers as showed in
Table 1 were designed to amplify the coding exons of the
SLC34A2 gene and the intronic flanking sequences. The
amplifications of all exons were performed in thermo-
cyclers (PerkinElmer, Inc, Foster City, Calif), starting with
an initial denaturation of 4 min at 95 C followed by 12
cycles of 35 s denaturation and 35 s annealing at 60 C
(0.5 C decrease in each cycle, and 40 s extension at 72 C).
After amplification, PCR products were run on 6% PAGE gel
to verify the specifities. Then, DNA sequencing was per-
formed in an ABI 3100 Genetic analyzer (Applied Bio-
systems, Invitrogen Company, Shanghai). All identified
disease-associated variants were examined for presence
in the 100 controls (200 chromosomes) by direct DNA
sequencing.
Literature review
We searched the articles in the PubMed (http://www.ncbi.
nlm.nih.gov/pubmed) and China National Knowledge
Infrastructure (CNKI) databases (http://www.cnki.net)
using the keyword “pulmonary alveolar microlithiasis,
SLC34A2”. All the papers were reviewed directly by two
investigators of our team. The mutation information of the
SLC34A2 gene from these articles was collected and rean-
alyzed together with our result for more comprehensive
knowledge about its role in this disease.
Results
Genotyping results
Member Ⅱ:9 in the consangeous family and the sporadic
case (member Ⅱ:7 from the non-inbred family) harbored
a same homozygous mutation c.910A > T (p.K304X) in the
SLC34A2 exon8 (Fig. 2), which was reported previously.
Figure 1 Family 1 and 2 with pulmonary alveolar microlithiasis (PAM) (square symbols, men; circular symbols, women; filled
symbols, PAM affected). Cross line indicates deceased. The probands are marked arrows. Family member Ⅰ:1 and Ⅰ:2 are first cousins
in family 1.
Table 1 Sequence of primers for amplification of PCR and
the length of products of amplification.
Sequence of primers Length
of
amplified
product
SLC34A2-1F:CCGTCGGAGCTTTTCTCTCGG
SLC34A2-1R:GTCGATCGTAAGAGTGTAGCAGC
477bp
SLC34A2-2-3F:GTTGATGCTTTGCAACCAATGG
SLC34A2-2-3R:TGATGACACCCACAGTGAACG
500bp
SLC34A2-4F:GCTCATTGCCAAACTTCTCAGG
SLC34A2-4R:GCTGGAGAGGGCTTGCTGA
300bp
SLC34A2-5F:GGCCTTGGATGGAGACTTCTG
SLC34A2-5R:TCCCACCCTCAGATAGACAGG
302bp
SLC34A2-6F:GGTAACTTTAGCCTGCCTCCAG
SLC34A2-6R:GCATGTCATCTTTGGCTGGTT
270bp
SLC34A2-7F:GAGGGTGGCAGATGATACAGG
SLC34A2-7R:TGTCAGCTCAGGTAGGGGATG
357bp
SLC34A2-8F:CCCTGGGTTTGTGTCCTAAATC
SLC34A2-8R:CTTCCTTGAAGGCAAGATTTAGTT
243bp
SLC34A2-9F:CATTGCCTCCCATTCCCCACT 241bp
The SLC34A2 gene mutation in PAM 219Family 1 memberⅢ:6 who was clinically unaffected showed
the same variant c.910A > T (p.K304X) in a single chro-
mosome (Fig. 2). Family 1 member Ⅱ:1 and 100 healthy
volunteers didn’t have this variant. No other variants in
exons 1e7 and 9e13 were detected. Immediate truncation
from Lys led by this mutation would result in premature
termination, which was predicted to cause loss of function
of the protein.
Review of SLC34A2 mutation in PAM
Eight articles involving 25 cases studied the SLC34A2 gene
mutations in PAM cases.8,10,15e21 One report of 3 cases was
eliminated from our analysis for unreliable result.15 Three
cases from an inbred Chinese family and one case from
Sweden showed negative results.10,21 Other 6 articles with
21 cases demonstrated multiple mutation symbols of the
SLC34A2 gene in PAM patients from China, Turkey, and
Japan respectively. Among these reports, three point
deletions, one deletion plus insertion mutation, five point
mutations, one small fragment deletion and one large
fragment deletion were identified (Table 2).SLC34A2-9R:AATAGGTCACCCCCAGACAAC
SLC34A2-10F:TAACAATCTGTAGCCGTGGTGG
SLC34A2-10R:GAATCTAAAGGACCCCCACAC
300bp
SLC34A2-11-12F:TGTACAACCTCACCCCTAAGCC
SLC34A2-11-12R:AGAGACCAGTTTGCAAGACCATG
499bp
SLC34A2-13-1F:TGTGATGCCTGCTAGCTTACCT
SLC34A2-13-1R:CAGCAGCGCATCTGGAAGCAG
492bp
SLC34A2-13-2F:CTGCCGAAGAAACTCCAGAACT
SLC34A2-13-2R:CCAAAGGGAATCGAGTTAGGTAG
481bpDiscussion
In present study, we described the clinical features and
SLC34A2 gene mutations in an inbred PAM family and an
unrelated, sporadic patient and reviewed SLC34A2 gene
mutations in PAM patients. Our diagnosis of PAM was
established based on the characteristic chest X-ray and CT
scan findings with the diffuse intra-alveolar lamellar
Figure 2 Sequence analysis of the c.910A > T mutation in the available members of family 1 and the sporadic patient of family 2.
The affected nucleotide was indicated with an arrowhead. An A to T homozygous mutation at nucleotide 910 (arrow) in the coding
region of exon8 of the SCL34A2 gene was observed in family 1 member Ⅱ:9 (B) and the sporadic patient (D). Family 1 member
Ⅲ:6(A) was detected a heterozygous mutation at the same site. The point mutation was not seen in family 1 member Ⅱ:1(C) and
healthy control (E).
220 X. Yin et al.microliths in the lung tissue without obvious clinical mani-
festation.3,7,22 Identification of a homozygous mutation in
the SLC34A2 gene further clinched the diagnosis.8,16,17
The clinical features of our patients were unremarkable
compared with previous reported cases.1e8,16e19,23 Both
cases showed early onset, slow developing course, no
obvious difference could be noted between the familial
cases and sporadic case, either. Though extrapulmonarycalcium deposits in testis, kidney, urethra, gallbladder and
aortic valve has been reported,5,6,23,24 our patients didn’t
present those complications. In spite of its slow develop-
ment, the prognosis of this disease is not as good as ex-
pected. Two (family 1 member Ⅱ:3 and Ⅱ:11) of three
familial cases died of respiratory failure. Lung trans-
plantation is suggested the only promising treatment,
though long-term result is not proved.
Table 2 SLC34A2 Sequence variants identified in patients with PAM.
Origin
of patient
Cases Mutation Location Effect on
translation
Predicted
consequence
on protein
Reference
Turkish 1 c.[-6773_-6588del] þ [-6773_-6588del] Promoter
exon1
. Not synthesized Ref. 17
Turkish 3 c.[114delA] þ [114delA] Exon3 Frameshift Truncation Ref. 17, Ref. 20
Turkish 1 c.[226C > T] þ [226C > T] Exon3 p.Q76X Truncation Ref. 17
Turkish 2 c.[316G > C] þ [316G > C] Exon4 p.G106R Substitution Ref. 17, Ref. 20
Japanese 2 c.[857-
871delinsAAGTTATCGCTTTTTCATC] þ
[857-871delinsAAGTTATCGCTTTTTCATC]
Exon7 Frameshift Truncation Ref. 16
Chinese 4 c.[910A > T] þ [910A > T]* Exon8 p.K304X Truncation Ref. 8
Japanese 4 c.[IVS8þ1G > A] þ [IVS8þ1G > A] Exon8 Aberrant splicing Truncation Ref. 16
Turkish 1 c.[1328delT] þ [1328delT] Exon11 Frameshift Truncation Ref. 17
Turkish 1 c.[1342delG] þ [1342delG] Exon12 p.V448X Truncation Ref. 17
Turkish 1 c.[1456C > T] þ [1456C > T] Exon13 p.Q486X Truncation Ref. 19
Japanese 1 a 5.5 kb long homozygous deletion Exon2e6 . . Ref. 18
* denotes the results of this paper.
The SLC34A2 gene mutation in PAM 221Though one third of cases are familial suggested genetic
basis might be the etiology of PAM, it is until 2006 the
SLC34A2 gene has been identified to be responsible for
PAM.16,17 However, currently we only collected 21 cases
about SLC34A2 gene mutation in PAM. In those reports,
eleven different mutations of SLC34A2 gene were detected
without obvious hotspot region among those patients.
Exon1, 2, 3, 4, 6, 7, 8, 11, 12 and 13 were involved mainly.
The mutation site in Turkish is versatile except exon7 and
exon8. Chinese patients only have mutation in exon8.
Japanese patients demonstrated a 5.5 kb long homozygous
deletion. All of those mutations were homozygous. Most of
these mutations happened on the exons, truncation of
protein was the predominant result of these mutations. All
the patients originated from different regions or countries.
Thus, it is more likely that the mutation is recurrent rather
than identical by descent. As for the different races,
Turkish obviously showed more involved exons, and the
mutation in Japanese and Chinese was relatively simple,
mainly in exon7 and exon8, which suggests exon7 and exon8
might be liable to be affected in. However, the mutation
symbols of their patients are quite different as we noted in
Table 2, in spite of the fact that Japanese and Chinese
belongs to the same race, Mongoloid, and are close in area.
This phenomenon might be explained by the influence of
environment and life style on genetics.
Our investigation demonstrated a reported mutation of
homozygous mutation (c.910A > T) in exon8 of the SLC34A2
gene, which caused premature termination. The truncated
protein lacking five functional domains is about half the
size of the full-length protein, and has definitely lost its
normal function. Although segregation of the mutation
could not be confirmed by studying all affected family
members due to the death of the two elder sisters, the
asymptomatic heterozygous carriers (family 1 member Ⅱ:9)
with normal chest X-ray finding provided the strong
evidence. In Chinese patients, both the two unrelated
affected familial patients and the sporadic patient had
the same nonsense mutation in the exon8 of SLC34A2
gene.8 The high consistency of the mutation site releasesa strong signal that exon8 might be a good target for future
gene screening in Chinese PAM cases. However, more cases
should be collected to confirm it.
No disease-causing mutations or single nucleotide poly-
morphisms in the SLC34A2 gene were identified in an
inbred, Chinese PAM family reported by Yang Y et al.10
Recently, the same result has been reported in a PAM
patient from Sweden.21 It suggests that PAM may be
a genetically heterogeneous entity that arises from muta-
tions in genes other than SLC34A2 although the mutation
could be in the 50 and 30 untranslated regions, intron and
copy number problems.17
In sum, our investigation revealed a homozygous muta-
tion of the SLC34A2 gene in PAM patients. The review of
literatures suggests that exon7 and exon8 seemed liable to
be affected typical Mongoloid of PAM, and exon8 might be
the screen target for Chinese patients.
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